Overview

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Status:
Available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.